Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBENS trial of obicetrapib with or without ezetimibe in adults with type 2 diabetes mellitus and/or metabolic syndrome
2025-521936-12-00Phase 3Authorised
- Sponsor
- NewAmsterdam Pharma
- Start
- Apr 2026
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and dyslipidemia comparing Obicetrapib + ezetimibe fixed-dose combination, Obicetrapib monotherapy and Placebo (3 arms). Planned start Apr 2026; status: authorised.
02
Drugs
obicetrapibezetimibe
03
Conditions
hypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on 2025-521936-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521936-12-00.